Article Dans Une Revue Arthritis & rheumatology Année : 2024

Towards the lowest efficacious dose (ToLEDo): results of a multicenter non‐inferiority randomized open‐label controlled trial assessing Tocilizumab or Abatacept injection spacing in rheumatoid arthritis in remission

1 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
2 PHERE (UMR_S_1152 / U1152) - Physiopathologie et Epidémiologie des Maladies Respiratoires
3 CHU Pitié-Salpêtrière [AP-HP]
4 SAINBIOSE - Santé Ingénierie Biologie Saint-Etienne
5 HLSO - Hôpital La Source [Orléans]
6 CHU de Bordeaux Pellegrin [Bordeaux]
7 Service de rhumatologie [Rennes] = Rheumatology [Rennes]
8 Service Rhumatologie [CHU Clermont-Ferrand]
9 PhyMedExp - Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046]
10 Service de Rhumatologie [Hôpital Lapeyronie - CHU Montpellier]
11 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
12 UT3 - Université Toulouse III - Paul Sabatier
13 Infinity - Institut Toulousain des Maladies Infectieuses et Inflammatoires
14 Service de Rhumatologie [CH Le Mans]
15 Hôpitaux de Chartres [Chartres]
16 VIEFRA - EA 3797 - Vieillissement, Fragilité
17 Hôpital Maison Blanche
18 Hôpitaux Sud - Rhumatologie [Sainte- Marguerite - APHM]
19 Service de rhumatologie [Strasbourg]
20 Höpital NOVO
21 ECaMO - [CRESS - U1153 / UMR_A 1125] - Clinical Epidemiology Applied to Osteoarticular Diseases | Épidémiologie clinique appliquée aux maladies rhumatismales et musculo-squelettiques
22 LBAI - Lymphocytes B, Autoimmunité et Immunothérapies
23 Service de Rhumatologie [CHU de Grenoble]
24 CHD Vendée - Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon
25 CIC - Centre d’Investigation Clinique [Tours] CIC 1415
26 IMVA-HB - Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes
27 Service de Rhumatologie [CHU Bicêtre]
28 CRSA - Centre de Recherche Saint-Antoine
29 Groupe Hospitalier du Havre
30 Centre hospitalier de Châteaudun
31 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
32 CHCB - Centre Hospitalier de la Côte Basque
33 Service de Rhumatologie (CHU de Dijon)
34 BIOSCAR (UMR_S_1132 / U1132) - Biologie de l'Os et du Cartilage : Régulations et Ciblages Thérapeutiques
35 Service de Rhumatologie [CHU Lariboisière]
36 HEMATIM - HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666
37 IDESP - Institut Desbrest de santé publique
38 Service de Rhumatologie [CHRU Nancy]
Carine Salliot
Edouard Pertuiset
  • Fonction : Auteur
Francis Berenbaum

Résumé

Objective To assess the clinical and structural impact at 2 years of progressively spacing tocilizumab (TCZ) or abatacept (ABA) injections versus maintenance at full dose in rheumatoid arthritis (RA) patients in sustained remission. Methods This multicenter open‐label non‐inferiority (NI) randomized clinical trial included patients with established RA in sustained remission receiving ABA or TCZ at a stable dose. Patients were randomized to treatment maintenance at full dose (M‐arm), or progressive injection spacing driven by the Disease Activity Score in 28 joints (DAS28) every 3 months up to biologics discontinuation (S‐arm). The primary endpoint was the evolution of disease activity according to DAS44 during the 2‐year follow‐up analysed per protocol with a linear mixed‐effects model, evaluated by an NI test based on the one‐sided 95% CI of the slope difference (NI margin: 0.25). Other endpoints were flare incidence and structural damage progression (SDP). Results Overall, 202 of the 233 patients included were considered for per protocol analysis (90 in S‐arm, 112 in M‐arm). At the end of follow‐up, 16.2% of the S‐arm patients could discontinue their bDMARD: 46.9% tapered the dose and 36.9% returned to a full dose. NI was not demonstrated for the primary outcome, with a slope difference of 0.10 [95% CI ‐0.10; 0.31] between the two arms. NI was not demonstrated for flare incidence (difference 42.6% [95%CI: 30.0; 55.1]) or rate of SDP at 2 years (difference 13.9% [95% CI: ‐6.7; 34.4]). Conclusions The ToLEDo trial failed to demonstrate NI for the proposed ABA or TCZ tapering strategy.
Fichier principal
Vignette du fichier
2023 Kedra et al., Towards the Lowest.pdf (826.77 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04279434 , version 1 (30-01-2024)

Identifiants

Citer

Joanna Kedra, Philippe Dieudé, Caroline Giboin, Hubert Marotte, Carine Salliot, et al.. Towards the lowest efficacious dose (ToLEDo): results of a multicenter non‐inferiority randomized open‐label controlled trial assessing Tocilizumab or Abatacept injection spacing in rheumatoid arthritis in remission. Arthritis & rheumatology, 2024, ⟨10.1002/art.42752⟩. ⟨hal-04279434⟩
262 Consultations
117 Téléchargements

Altmetric

Partager

More